Article
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
mAbs - 1 Jan 2014
Hervé Virginie, Rabbe Nathalie, Guilleminault Laurent, Paul Flora, Schlick Laurène, Azzopardi Nicolas, Duruisseaux Michael, Fouquenet Delphine, Montharu Jérôme, Redini Françoise, Paintaud Gilles, Lemarié Etienne, Cadranel Jacques, Wislez Marie, Heuzé-Vourc'h Nathalie
Abstract excerpt
K-ras mutations promote angiogenesis in lung cancer and contribute to the drug resistance of cancer cells. It is not clear whether K-ras mutated adenocarcinomas are sensitive to anti-angiogenic therapy with monoclonal antibodies (mAbs) that target vascular endothelial growth factor (VEGF). Anti-angiogenic mAbs are usually delivered systemically, but only a small proportion reaches the lung after intravenous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.